RT Journal Article
T1 Safety of renal biopsy bleeding prophylaxis with desmopressin.
A1 Barrios, R Haridian Sosa
A1 Burguera Vion, Víctor
A1 Álvarez Nadal, Marta
A1 Cintra Cabrera, Melissa
A1 Elías Triviño, Sandra
A1 Villa Hurtado, Daniel
A1 Ortego, Sofía
A1 Fernández Lucas, Milagros
A1 Rivera-Gorrin, Maite
K1 1-deamino8-D-arginine vasopressin
K1 Renal biopsy
K1 bleeding
K1 cardiovascular event
K1 desmopressin safety
K1 hyponatraemia
K1 interventional nephrology
K1 prophylaxis
K1 secondary effect
K1 uraemia
AB Percutaneous renal biopsy (PRB) is invasive, and bleeding-related complications are a concern. Desmopressin (DDAVP) is a selective type 2 vasopressin receptor-agonist also used for haemostasis. To evaluate the side effects of intravenous (IV) weight-adjusted desmopressin preceding PRB. This was a retrospective study of renal biopsies performed by nephrologists from 2013 to 2017 in patients who received single-dose DDAVP pre-PRB. Of 482 PRBs, 65 (13.5%) received DDAVP (0.3 µg/kg); 55.4% of the PRBs were native kidneys. Desmopressin indications were altered platelet function analyser (PFA)-100 results (75.3% of the patients), urea >24.9 mmol/L (15.5%), antiplatelet drugs (6.1%) and thrombocytopaenia (3%). Of the 65 patients, 30.7% had minor asymptomatic complications, and 3 patients had major complications. Pre-PRB haemoglobin (Hb) 24.9 mmol/L (15.5%), antiplatelet drugs (6.1%) and thrombocytopaenia (3%). Of the 65 patients, 30.7% had minor asymptomatic complications, and 3 patients had major complications. Pre-PRB haemoglobin (Hb) 10 g/L, and altered collagen-epinephrine (Col-Epi) time was a significant risk factor for overall complications. Mean sodium decrease was 0.6 ± 3 mmol/L. Hyponatraemia without neurological symptoms was diagnosed in two patients; no cardiovascular events occurred. Hyponatraemia after single-dose DDAVP is rare. A single IV dose of desmopressin adjusted to the patient's weight is safe as pre-PRB bleeding prophylaxis.
YR 2021
FD 2021
LK https://hdl.handle.net/10668/27589
UL https://hdl.handle.net/10668/27589
LA en
DS RISalud
RD Apr 6, 2025